GSK and ViiV score breakthrough therapy designation in HIV prevention, as Truvada showdown draws nearer

GSK and ViiV score breakthrough therapy designation in HIV prevention, as Truvada showdown draws nearer

Source: 
Endpoints
snippet: 

A little less than a week after beefing up the data package it plans to take to the FDA for the experimental HIV drug cabotegravir, GSK-owned ViiV Healthcare has received good news on the medicine’s prospects.